Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis

NCT00051662 is registered in ClinicalTrials.gov with XOMA (US) LLC as lead sponsor.

NCT NCT00051662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis
Lead sponsor
XOMA (US) LLC
Phase
Phase 1
Overall status
Completed
Start date
Not reported
Completion date
February 29, 2004
Enrollment
45
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis